Donate
T1International Launches 100 Years: From Gift to Greed Campaign

T1International Launches 100 Years: From Gift to Greed Campaign

Facebook Google LinkedIn Twitter

CHELTENHAM, England – On Monday, May 17th - 100 years after Banting, Best and Macleod begin their first experiment trying to extract insulin in Toronto - T1International and its advocates around the world launch their year-long campaign. 100 Years: From Gift to Greed will tell the story of insulin’s discovery and how it went from being a gift to the world to a profit machine for the pharmaceutical industry. The campaign will be led by a combination of social media education and a variety of actions.

Insulin is as essential as oxygen for all patients with type 1 diabetes and many with type 2 or other forms of insulin-dependent diabetes. Globally, insulin rationing is common, and half of those in need of insulin cannot afford or access it. For every two people alive with type 1 diabetes, there is a third who did not survive. The production and distribution of insulin is dominated by three companies - Eli Lilly, Novo Nordisk, and Sanofi - who control more than 90% of the global market.

In the early 1920s in Toronto, Canadian physician and scientist Frederick Banting began working on an idea in the laboratories of J.R.R. McLeod to isolate and extract insulin. Medical student Charles Best and chemist James Collip worked with Banting to test, purify and refine insulin for clinical trials in humans.

After vowing that insulin would not be something to profit on, the discoverers sold their patent for $1 CAD each and eventually passed the rights to the pharmaceutical company Eli Lilly and Co. so that it could be mass produced and widely available. Banting famously said, ‘’Insulin does not belong to me, it belongs to the world.’’

While this incredible advancement was intended as a gift from the discoverers, Eli Lilly and the two other major insulin producers, Sanofi and Novo Nordisk, have turned insulin into profit machines, assisting in bringing in billions of dollars in profit every year. By 1923, insulin was the highest-selling product in Eli Lilly’s history, and profits from it accounted for over half of the company’s revenue. As we know, the prices have continued to skyrocket ever since. Since 1996, the list price of insulin has increased by over 1200% in the United States. Eli Lilly’s Humalog insulin increased in price by 585% between 2001 and 2015 alone.

T1International’s Founder and Executive Director, Elizabeth Pfiester, said, ‘‘A gift to the world has become a tool for price gouging patients all over the world. The greed of the pharmaceutical industry is keeping insulin out of the hands of millions. This greed leads to the loss of countless lives and dampens the dream of Banting and his colleagues, which was to make insulin a gift to the world. It is outrageous that this is the reality, and T1International will continue to speak out until the pharmaceutical industry is held accountable.’’

T1International advocates will be speaking out and educating the community about the story of insulin and how to get involved in T1International and the global #insulin4all movement. The aim is to put an end to the reality that far too many people die or suffer grave physical, mental, and emotional health consequences due to pharmaceutical greed.

Visit the campaign page and read more at: t1international.com/100years

Questions about T1International and this campaign should be directed to press@t1international.com.

Related posts:

T1International’s 2022 Out-of-Pocket Cost Survey: An Easy Way to Advocate

T1International’s 2022 Out-of-Pocket Cost Survey: An Easy Way to Advocate

Take the Survey! The survey is for individuals over the age of 18 with type 1 diabetes. A parent or caregiver can take the survey for those under the age of 18. Caregivers can also take the survey for spouses or partners. The survey is anonymous and is completely optional. Read more

T1International Statement on HR 6833 and the Affordable Insulin Now Act Vote

T1International Statement on HR 6833 and the Affordable Insulin Now Act Vote

On Thursday, March 31st, the US House of Representatives voted to pass a $35 insulin copay cap. The bill now heads to the Senate. While a $35 copay cap on insulin would impact many people, T1International is calling on the Senate to pass a true price cap on insulin for everyone, especially those without insurance. Read more

The Next 100 Years of Insulin

The Next 100 Years of Insulin

For some, the first 100 years of insulin has been a great, life-affirming success. For others, it has been a failure, where leaders and organizations in power have chosen profits over the lives and welfare of human beings. So how will we shape the next 100 years? Read more

T1International Publishes Survey on Type 1 Diabetes, COVID, and Insulin Rationing

T1International Publishes Survey on Type 1 Diabetes, COVID, and Insulin Rationing

In September 2021, T1International’s latest out-of-pocket cost survey was published in the Journal of Diabetes Research and Clinical Practice. Conducted every two years, this study is the most comprehensive patient-led out-of-pocket cost survey for people living with type 1 diabetes. Read more

T1International Hosts 3rd Annual #insulin4all Workshop

T1International Hosts 3rd Annual #insulin4all Workshop

Join us for T1International’s annual #insulin4all Workshop: Advocate, Don’t Celebrate. This event is an opportunity for advocates from around the world to learn from each other, build community, and take action in the fight for #insulin4all. Read more

T1International Year in Review: 2020

T1International Year in Review: 2020

What a year we had as a community and as an organization in 2020. There were many global challenges, as always, and COVID-19 had huge impacts across the world. Below is a taste of what, thanks to our advocates and supporters, we achieved. Read more

T1International Statement on #insulin4all

T1International Statement on #insulin4all

T1International has been made aware of a recent increase in hateful speech, as well as disrespectful and non-collaborative behavior on the #insulin4all hashtag. While hashtags cannot be owned by anyone, T1International’s global work is tied to #insulin4all. As one of the creators of the hashtag, we want to acknowledge our concerns over these issues and set clear lines about what we stand for as an organization, and what we do not. Read more

T1International Launches Communities of Color Campaign

T1International Launches Communities of Color Campaign

As the celebration of Black History Month is underway in the United States, T1International is launching its Communities of Color campaign. This campaign aims to highlight the need for better representation and genuine inclusion of people of color (PoC) within the diabetes community and to encourage participation and inclusion of PoC in the #insulin4all movement fighting for access to affordable insulin and diabetes care. Read more

8 Reasons Why Insulin is so Outrageously Expensive

8 Reasons Why Insulin is so Outrageously Expensive

Why does insulin cost so much to patients in the USA and around the world? Why is insulin, a widely sold drug of which most forms are now off-patent, so incredibly expensive? These are simple questions, but ones with a number of complicated answers. This post will break some of those answers down and point you in the direction further reading if you want to dive deeper. Read more